17-58724057-G-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4BP6
The NM_058216.3(RAD51C):c.922G>T(p.Ala308Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000279 in 1,613,282 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000131 AC: 20AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251384Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135856
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461026Hom.: 0 Cov.: 30 AF XY: 0.0000165 AC XY: 12AN XY: 726874
GnomAD4 genome AF: 0.000131 AC: 20AN: 152256Hom.: 0 Cov.: 32 AF XY: 0.000134 AC XY: 10AN XY: 74440
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
- -
Observed in individuals with prostate cancer and Lynch syndrome-related cancer and/or polyps (PMID: 25980754, 32832836); In silico analysis indicates that this missense variant does not alter protein structure/function; Published functional studies demonstrate no damaging effect on protein interactions, and classified as functional based on a saturation genome editing assay assessing cell fitness (PMID: 36099300, 39299233); This variant is associated with the following publications: (PMID: 33471991, 32832836, 25980754, 14704354, 39299233, 36099300) -
RAD51C: BP4, BS3:Supporting -
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
- -
The p.A308S variant (also known as c.922G>T), located in coding exon 7 of the RAD51C gene, results from a G to T substitution at nucleotide position 922. The alanine at codon 308 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:2Benign:1
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
- -
The RAD51C c.922G>T (p.Ala308Ser) missense change has a maximum subpopulation frequency of 0.068% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. Four individual(s) with this variant are reported in a database of women older than 70 years of age who have never had cancer (FLOSSIES, https://whi.color.com/). To our knowledge, this variant has not been reported in individuals with hereditary breast and ovarian cancer or Fanconi anemia. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
not specified Uncertain:1
Variant summary: RAD51C c.922G>T (p.Ala308Ser) results in a conservative amino acid change located in the C-terminal domain (IPR013632) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 251384 control chromosomes. Although the available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance for Autosomal Recessive Fanconi Anemia Complementation Group O, the variant allele was found at a frequency of 7.3e-05 in 396098 control chromosomes (gnomAD v2.1 and v3.1-non-v2 datasets), and was exclusively reported within the African or African-American subpopulation at a frequency of 0.00054. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 8-fold of the estimated maximal expected allele frequency for a pathogenic variant in RAD51C causing Hereditary Breast and Ovarian Cancer Syndrome phenotype (6.3e-05), suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. In addition, the variant has also been reported in 4 / 2559 African American women, who are older than age 70 and cancer free (FLOSSIES database). c.922G>T has been reported in the literature in an individual affected with breast cancer (Dorling_2021) and another individual affected with a tumor that belongs to the Lynch syndrome tumor spectrum (Yurgelun_2015), however no supportive evidence for causality was provided. These report(s) do not provide unequivocal conclusions about association of the variant with Fanconi Anemia Complementation Group O or Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 33471991, 32832836, 25980754). ClinVar contains an entry for this variant (Variation ID: 186543). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Fanconi anemia complementation group O;C3150659:Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
- -
RAD51C-related disorder Uncertain:1
The RAD51C c.922G>T variant is predicted to result in the amino acid substitution p.Ala308Ser. This variant has been reported in an individual undergoing Lynch syndrome testing (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754) and in an individual with breast cancer (Table S22, Dorling et al. 2021. PubMed ID: 33471991). This variant is reported in 0.068% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-56801418-G-T) and has conflicting interpretations of likely benign and uncertain in the ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/186543/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Fanconi anemia complementation group O Uncertain:1
This sequence change replaces alanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 308 of the RAD51C protein (p.Ala308Ser). This variant is present in population databases (rs185057307, gnomAD 0.07%). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 25980754). ClinVar contains an entry for this variant (Variation ID: 186543). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt RAD51C protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at